Three Chinese Biotech Startups Secure New Funding Rounds, Advancing Radiopharmaceuticals, iPSC Cell Therapies, and AI-Driven PPI Degraders

　　【Pharmaceutical Network Industry DynamicsFrom March 9 to March 15, at least five emerging pharmaceutical companies dedicated to innovative drug development worldwide announced the completion of a new round of financing. This includes three Chinese companies: Eli Radiopharma, PharmNoah Intelligence, and Suzhou Aikailiyuan Biotechnology Co., Ltd.
 

Eli Radiopharma Announces Completion of Nearly 100 Million Yuan in New Round of Financing on March 12
 

Data shows that Eli Radiopharma is a biopharmaceutical company focused on the research and development of innovative radiopharmaceuticals. The company specializes in oncology and neuroscience, striving to build an integrated radiopharmaceutical solution for both diagnosis and treatment. By combining molecular targeting technology with radionuclide technology, the company is developing diagnostic and therapeutic products that are both highly effective and safe, providing global patients with more precise diagnostic tools and more effective treatment options to help improve human health and quality of life. To date, Eli Radiopharma has completed over 300 million yuan in cumulative financing, reflecting continued confidence from the capital market in its technological approach and business model.
 

PharmNoah Intelligence announced on March 11 the completion of an angel round of financing worth nearly RMB 100 million. The funds from this round of financing will be used for three main purposes: specifically, the funds will be used to accelerate the preclinical candidate molecule development and IND application for the STAT6 project, comprehensively advance the IND application for the core pipeline degrader PPI-101, and expedite the rapid optimization and iteration of the AI drug discovery platform based on protein-protein interactions. The company stated that the completion of this financing marks a new milestone for PharmNoah Intelligence as it officially enters a phase of leapfrog development.
 

Data shows that PharmNoah Intelligence is an innovative pharmaceutical company focusing on "undruggable targets." With protein-protein interaction (PPI) as the core starting point, the company deeply integrates AI technology to precisely identify novel druggable sites and efficiently advance drug discovery and development. Targeting major disease areas such as autoimmune disorders and cancer, PharmNoah Intelligence has established a full-chain drug design system that starts with PPI and ends with druggability.
 

Suzhou Aikailiyuan Biotechnology Co., Ltd. announced on March 9 the completion of an over 100-million-yuan Series A3 financing round. The funds will be mainly used to accelerate the clinical development of multiple allogeneic universal iPSC-derived cell therapies developed through an AI-driven R&D system. At the same time, the company will expedite the strategic layout of its two key technology platforms: iPSC-based cell therapy and iPSC-derived organoids, providing resource support for the clinical advancement of core products. This also marks a critical validation phase for the company’s AI-driven cell therapy and drug screening platform development model.
 

Data shows that Aikai Bio is an innovative biotechnology enterprise focusing on the development of iPSC cell therapy. Relying on its self-developed next-generation iPSC cell reprogramming platform, AI-driven iPSC cell and organoid differentiation platform, precise gene editing platform, and cell manufacturing that meets international clinical standards, the company focuses on immunology and regenerative medicine therapies to provide universal, effective, and accessible cell therapy drugs for patients worldwide. With the support of its self-constructed AI-driven predictive model system, Aikai Bio has formed a systematic iPSC cell drug research and development pathway, covering innovative directions such as neurological diseases like Parkinson's disease and epilepsy. The company has established an AI-driven R&D platform with independent intellectual property, deeply integrating algorithm models with experimental data, spanning key aspects such as cell reprogramming, optimization of directed differentiation pathways, and quality control.
 

In addition, among foreign innovative pharmaceutical companies, Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, announced on March 11 the completion of a $40 million Series A extension financing, bringing the total Series A financing to $100 million. Tacit Therapeutics announced on March 9 the completion of a $19 million Series A financing to develop RNA editing therapies for refractory neurological diseases.
 

Through this round of financing, it was found that technology-driven has become the core logic. High-barrier technical routes such as radiopharmaceuticals, cell therapy, RNA editing, and molecular glue degraders are highly favored; AI permeates the R&D process, upgrading from an auxiliary tool to core productivity; in addition, funds are preferentially directed towards pipeline projects with clear clinical needs and fast advancement speeds.
 

Innovative drugs are the core engine driving the high-quality development of the pharmaceutical industry and a golden track for long-term capital investment. With continuous capital infusion, companies such as Eli Radiopharma, PharmNoah Intelligence, and Suzhou Aikailiyuan Biotechnology Co., Ltd. are expected to accelerate technology transformation and clinical implementation.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.